Tanturri De Horatio C, Tirri E, Valletta R, Tirri G, Rengo S
Cattedra di Odontoiatria Conservativa, Università Federico II, Napoli.
Minerva Stomatol. 2000 Sep;49(9):409-13.
A large number of orofacial abnormalities have been described in patients with Systemic Sclerosis (SSc) but no data are reported on the correlation with different subgroups of patients on the efficacy of different therapies.
In the present study mouth opening was retrospectively evaluated in 40 patients with SSc in whom measurement of interlabial distance was taken at the first clinical control and during follow-up. The data confirmed that the mouth opening is significantly decreased in patients with SSc independently from sclerosis subgroup, age or disease duration.
Follow-up (8 +/- 8.3 years) showed a different behaviour of the parameter: in 12 patients (group I) no variation in mouth opening was detected, in 18 patients (group II) a decrease and in 10 patients (group III) an increase was observed.
The only difference between the three groups was the treatment received: 80% of the patients of group III (p < 0.01) have been treated with cyclophosphamide (CF). Our data further support the efficacy of treatment with CF in patients with SSc.
系统性硬化症（SSc）患者中已描述了大量口面部异常情况，但尚无关于不同治疗方法疗效与不同患者亚组之间相关性的数据报道。
在本研究中，对40例SSc患者的张口情况进行了回顾性评估，这些患者在首次临床检查时及随访期间测量了唇间距离。数据证实，SSc患者的张口度显著降低，与硬化亚组、年龄或病程无关。
随访（8±8.3年）显示该参数有不同表现：12例患者（I组）未检测到张口度变化，18例患者（II组）张口度降低，10例患者（III组）张口度增加。
三组之间的唯一差异在于接受的治疗：III组80%的患者（p<0.01）接受了环磷酰胺（CF）治疗。我们的数据进一步支持了CF治疗SSc患者的疗效。
